Symberix, Inc. articles

Durham, NC (April 28, 2020) - A review article published in PNAS highlights Symberix`s efforts to understand the role of the human microbiota in drug efficacy and toxicity. Symberix co-founder Matt Redinbo is featured in the article alongside other leaders from the emerging field of “pharmacomicrobiomics” -- the study of mechanisms behind the microbial impact on drug metabolism.

"U

Durham, NC (February 3, 2020) - An article in Nature highlights Symberix`s efforts to understand the complex relationship between drugs and the microbiome. The paper discusses recent contributions to the emerging field of “pharmacomicrobiomics” -- the study of how microbes impact drug disposition, efficacy, and toxicity. Symberix is developing bacteria-targeted small molecules that